Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines

Thongchot, Suyanee; Jamjuntra, Pranisa; Prasopsiri, Jaturawitt; Thuwajit, Peti; Sawasdee, Nunghathai; Poungvarin, Naravat; Warnnissorn, Malee; Sa-nguanraksa, Doonyapat; O-charoenrat, Pornchai; Yenchitsomanus, Pa‐thai; Thuwajit, Chanitra

doi:10.3892/or.2021.8205

Cited by 4 publications

(4 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PC-B-142CA (HER2 + subtype) and PC-B-148CA (triple-negative subtype) BCA cells were derived from the cancer tissues of two patients admitted at the Faculty of Medicine Siriraj Hospital, Mahidol University [ 13 ]. The cells were maintained in DMEM/F12 medium (Gibco, ThermoFisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (FBS) and 1 U/ml penicillin G sodium and 1 mg/ml streptomycin (ThermoFissher Scientific, Waltham, MA) at 37 °C in humidified 5% CO 2 incubator.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Stimulating T cell responses against patient-derived breast cancer cells with neoantigen peptide-loaded peripheral blood mononuclear cells

Sueangoen,

Grove,

Chuangchot

et al. 2024

Cancer Immunol Immunother

Self Cite

View full text Add to dashboard Cite

Breast cancer stands as a formidable global health challenge for women. While neoantigens exhibit efficacy in activating T cells specific to cancer and instigating anti-tumor immune responses, the accuracy of neoantigen prediction remains suboptimal. In this study, we identified neoantigens from the patient-derived breast cancer cells, PC-B-142CA and PC-B-148CA cells, utilizing whole-genome and RNA sequencing. The pVAC-Seq pipeline was employed, with minor modification incorporating criteria (1) binding affinity of mutant (MT) peptide with HLA (IC50 MT) ≤ 500 nm in 3 of 5 algorithms and (2) IC50 wild type (WT)/MT > 1. Sequencing results unveiled 2513 and 3490 somatic mutations, and 646 and 652 non-synonymous mutations in PC-B-142CA and PC-B-148CA, respectively. We selected the top 3 neoantigens to perform molecular dynamic simulation and synthesized 9–12 amino acid neoantigen peptides, which were then pulsed onto healthy donor peripheral blood mononuclear cells (PBMCs). Results demonstrated that T cells activated by ADGRL1E274K, PARP1E619K, and SEC14L2R43Q peptides identified from PC-B-142CA exhibited significantly increased production of interferon-gamma (IFN-γ), while PARP1E619K and SEC14L2R43Q peptides induced the expression of CD107a on T cells. The % tumor cell lysis was notably enhanced by T cells activated with MT peptides across all three healthy donors. Moreover, ALKBH6V83M and GAAI823T peptides from PC-B-148CA remarkably stimulated IFN-γ- and CD107a-positive T cells, displaying high cell-killing activity against target cancer cells. In summary, our findings underscore the successful identification of neoantigens with anti-tumor T cell functions and highlight the potential of personalized neoantigens as a promising avenue for breast cancer treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Herein, neoantigens were identified in two primary cancer cells derived from in-house patient-derived primary breast cancer cells [ 13 ]. The prioritized candidate neoantigens determined the actual binding with the HLA class I allele restricted to the patient by molecular dynamic (MD) simulation.…”

Section: Introductionmentioning

confidence: 99%

Stimulating T cell responses against patient-derived breast cancer cells with neoantigen peptide-loaded peripheral blood mononuclear cells

Sueangoen,

Grove,

Chuangchot

et al. 2024

Cancer Immunol Immunother

Self Cite

View full text Add to dashboard Cite

show abstract

“…The samples were designated Si-TGCT-1, Si-TGCT-2, Si-TGCT-3, and Si-TGCT-4. A fresh TGCT tissue sample (1 × 1 × 1 cm 3 ) was isolated from TGCT tissue and surgically resected according to our previous guidelines [ 21 ]. Briefly, TGCT tissues were incubated in a 10X antibiotic mixture (1 U/ml penicillin G sodium and 1 mg/ml streptomycin; Thermo Fisher Scientific Inc.), diluted in DMEM/F12.…”

Section: Methodsmentioning

confidence: 99%

“…Briefly, cells were permeabilized with 0.2% Triton-1X PBS and incubated overnight at 4 °C with the following primary antibodies: mouse anti-human panCK antibody (sc-8018; Santa Cruz Biotechnology Inc.); mouse anti-human CK-19 antibody (Santa Cruz Biotechnology Inc.); mouse anti-human α-SMA antibody (Sigma-Aldrich; Merck KGaA); rabbit anti-human fibroblast activation protein (FAP) antibody (ab53066; Abcam); and rabbit anti-human CSF-1R antibody (ab205921; Abcam). The goat anti-mouse IgG-Cy3 antibody (#115-166-071; Jackson ImmunoResearch Laboratories Inc.) or the donkey anti-rabbit IgG (H + L) highly cross-adsorbed secondary antibody Alexa Fluor 488 (21,206; Thermo Fisher Scientific Inc.) was used. The nuclei were stained with Hoechst 33,342 (Invitrogen; Thermo Fisher Scientific Inc.).…”

Section: Detection Of Markers By Immunofluorescence Stainingmentioning

confidence: 99%

Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis

et al. 2022

Self Cite

View full text Add to dashboard Cite

Tenosynovial giant cell tumor (TGCT) is a mesenchymal tumor derived from the synovium of the tendon sheath and joints, most frequently in the large joints. The standard of care for TGCTs is surgical resection. A new targeting approach for treating TGCTs has emerged from studies on the role of the CSF1/CSF1 receptor (CSF1R) in controlling cell survival and proliferation during the pathogenesis of TGCTs. We established four novel cell lines isolated from the primary tumor tissues of patients with TGCTs. The cell lines were designated Si-TGCT-1, Si-TGCT-2, Si-TGCT-3, and Si-TGCT-4, and the TGCT cells were characterized by CSF1R and CD68. These TGCT cells were then checked for cell proliferation using an MTT assay and three-dimensional spheroid. The responses to pexidartinib (PLX3397) and sotuletinib (BLZ945) were evaluated by two-dimensional MTT assays. All cells were positive for α‑smooth muscle actin (α‑SMA), fibroblast activation protein (FAP), CSF1R, and CD68. Except for Si-TGCT-4, all TGCT cells had high CSF1R expressions. The cells exhibited continuous growth as three-dimensional spheroids formed. Treatment with pexidartinib and sotuletinib inhibited TGCT cell growth and induced cell apoptosis correlated with the CSF1R level. Only Si-TGCT-4 cells demonstrated resistance to the drugs. In addition, the BAX/BCL-2 ratio increased in cells treated with pexidartinib and sotuletinib. With the four novel TGCT cell lines, we have an excellent model for further in vitro and in vivo studies.

show abstract

Current understanding of adenoid cystic carcinoma in the gene expression and targeted therapy

et al. 2023

View full text Add to dashboard Cite

Adenoid Cystic Carcinoma (ACC) has been considered as a "quiet" tumor. It is typically malignancy arising from exocrine glands with poor long-term prognosis due to high rate of recurrence and distant metastasis. It is characterized by perineural infiltration, distant metastasis, and positive incision edge. Surgery is the first line treatment for ACC, followed by cytotoxic chemotherapy and/or radiotherapy as adjuvant treatments to avoid recurrence. But recurrence or metastasis still occurs in more than 50% ACC. Recurrent and/or metastasis (R/M) ACC is usually incurable, and no systemic agent has been found effective. With the widespread use of whole exome sequencing (WES) and whole genome sequencing (WGS), its internal oncogenic mechanism is gradually revealed, which involving molecular mutations such as the MYB family gene translocation, Notch signal pathway, DNA damage repair (DDR) pathway and epigenetic molecular mutations. The review helps us to understand the linkage among the pathways and targeted genes in diagnosis and related treatment of ACC till now.

show abstract

Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines

Cited by 4 publications

References 55 publications

Stimulating T cell responses against patient-derived breast cancer cells with neoantigen peptide-loaded peripheral blood mononuclear cells

Stimulating T cell responses against patient-derived breast cancer cells with neoantigen peptide-loaded peripheral blood mononuclear cells

Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis

Current understanding of adenoid cystic carcinoma in the gene expression and targeted therapy

Contact Info

Product

Resources

About